DVDiego Vila

Diego Vila

*This is an algorithmically generated author record based on publicly available information.

Diego Vila has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Regional patterns of advanced therapy use and unmet disease control in axial spondyloarthritis across Latin America: a report from the ESPALDA-PANLAR registry

    by Rodrigo García-Salinas, Fernando Sommerfleck, Wilson Bautista-Molano, Guillermo Guaracha Basañez, Julio César Casasola Vargas, Daniel Fernández-Ávila, Diego Vila, María Lorena Brance, Jossiell Then Báez, Francisco Zevallos Miranda, et al.

  • Profile of patients with axial spondyloarthritis in Latin America: first report from the ESPALDA-PANLAR registry

    by Fernando Sommerfleck, Rodrigo Garcia-Salinas, Diego Vila, Daniel Palleiro, Daniel G. Fernández-Ávila, Julio César Casasola-Vargas, Yelena Sanchez-Canto, Liliana Candia, Nicolás Marín Zúcaro, Maria Lorena Brance, et al.

    Despite increasing recognition of axial spondyloarthritis (axSpA) in Latin America, regional data remain scarce. This study aims to describe the clinical, laboratory, and imaging features of axSpA in Latin America using data from the ESPALDA-PANLAR registry. A cross-sectional analysis was conducted using baseline data from the ESPALDA registry, which includes patients with axSpA across seven Latin American countries. Demographic, clinical, laboratory, and imaging data were collected. Patients were stratified by sex, HLA-B27 status, and radiographic classification. Multivariable logistic regression was performed to identify independent associations. A total of 220 patients were included (56% male), with a mean age of 46 years and median diagnostic delay of 93 months (IQR: 13–122). HLA-B27 was positive in 60% of patients, and 62% met radiographic axSpA classification criteria. In multivariable analysis, radiographic axSpA was independently associated with male sex (OR 4.22; 95% CI 1.53–11.59), SI joint erosions on MRI (OR 3.98; 95% CI 1.45–10.90), and longer diagnostic delay (OR 1.01 per month; 95% CI 1.00–1.01). HLA-B27 positivity was associated with bone marrow edema on MRI (OR 2.81; 95% CI 1.50–5.26) and inversely with psoriasis (OR 0.14; 95% CI 0.06–0.33). This first report from the ESPALDA registry highlights distinctive features of axSpA in Latin America, including lower HLA-B27 prevalence and remarkably diagnostic delay. These findings underscore the need for earlier recognition and regionally adapted strategies for diagnosis and management.


  • Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina

    by María Victoria Martire, Josefina Marin, Hernán Maldonado-Ficco, Mariana Benegas, Pamela Giorgis, Diego Vila, Carolina Ayelen Isnardi, María Julieta Gamba, Javier Federico Flores-Trejo, Rodolfo Perez-Alamino, et al.

    Objective: To describe the access, effectiveness, survival, and adverse events (AEs) of secukinumab (SEC) in patients with axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA).Methods: In a multicenter, observational, retrospective cohort study, patients ≥ 18 years with axSpA or axPsA who had received ≥ 1 dose of SEC were included. The number of days between the request for the drug and the first application was calculated. Effectiveness was defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) < 4 at 6 months. Drug survival was analyzed using Kaplan-Meier curves and Cox regression analysis.Results: One hundred seventeen patients were included: 72 (61.5%) with axPsA and 45 (38.5%) with axSpA. Those having public health insurance presented a longer delay in receiving SEC (median 90 days [IQR 60-150]) vs those using the social security system (P= 0.01) and those with private health coverage (P= 0.009). Effectiveness of SEC after 6 months was achieved in 72/117 patients (61.5%): 44/72 patients with axial PsA (61.5%) and 28/45 patients with axSpA (62.2%;P= 0.91). The median SEC survival was 48 months (95% CI 32-63). The only factor associated with reduced survival was SEC as third-line treatment or higher (hazard ratio 3.43, 95% CI 1.11-11.10;P= 0.04). The incidence of AEs was 7.9 events/100 patients/year (95% CI 5-12).Conclusion: The delay in receiving SEC was longer in patients with public health insurance. Patients using SEC as third-line or higher therapy had 3.4 times less survival. AEs were mild and no AEs of interest were observed.